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The quality of a clinical study depends on internal and
external factors. Studies have internal validity when, random
error apart, reported differences between exposed and
unexposed individuals can be attributed only to the exposure
under investigation. Internal validity may be affected by bias,
that is, by any systematic error that occurs in the design or in
the conduction of a clinical research. Here we focus on two
major categories of bias: selection bias and information bias.
We describe three types of selection biases (incidence-
prevalence bias, loss-to-follow-up bias, and publication
bias) and a series of information biases (i.e. misclassification
bias—recall bias, interviewer bias, observer bias, and
regression dilution bias—and lead-time bias).
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If an experiment was conducted to find out the distribution
of sizes of fish in a lake, a net could be used to catch a
representative sample of fish. If net had a mesh size of 1 cm then
no fish with sizes less than 1 cm would be found. This is a result
of the method of selection (selection bias) from the experiment,
there is no way of knowing whether there are any fish smaller
than 1 cm.
From Wikipedia: http://en.wikipedia.org/wiki/Selection_bias
The quality of a clinical study depends on internal and
external factors. Studies have internal validity when, random
error apart, reported differences between exposed and
unexposed individuals can be attributed only to the exposure
under investigation. Internal validity can be affected by two
types of error: random error and systematic error. Random
error depends on chance and can be minimized by increasing
the sample size.1 For example, if we measure serum
creatinine three times in the same individual by using the
same instrument and the same laboratory reagents, we can
obtain slightly different values as a result of clinical
fluctuations in the measurement. Systematic errors depend
on any flaw that systematically leads to an overestimation or
underestimation of the measurement and this type of
error is independent of sample size.1 Systematic error
occurs if the device we use, for example a sphygmoman-
ometer for measuring blood pressure (BP), systematically
overestimates or underestimates the ‘true’ BP of the
subject being evaluated. Systematic error is also referred to
as bias. The list of biases is a long one.2 Here, we focus on
two major categories of bias: selection bias and information
bias. Confounding, which some authors consider also
as a kind of bias, will be described in a future article of
this series.
SELECTION BIAS (OR BERKSONIAN BIAS)
This type of error occurs when a systematic error in the
enrollment of individuals in a study—cases or controls in
case–control study, or exposed or unexposed individuals in a
prospective cohort study—determines a biased association
between exposure and outcome. Here we consider three types
of selection bias: the incidence-prevalence bias (Examples 1
and 2), the loss-to-follow-up bias, and the publication bias
(Example 3).
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Incidence-prevalence bias
An important selection bias is the incidence-prevalence bias
(or Neyman bias or survival bias), that is, a bias that occurs
when we try to estimate the risk of a disease on the basis of
data collected at a given time point in a series of survivors
rather than on data gathered during a certain time period in a
group of incident cases (Example 1), or when the sample of
cases offers a distorted frequency of the exposure (Example
2). This type of bias is of particular relevance in cross-
sectional studies.
Example 1: We consider a cohort of 20 individuals with a
follow-up from t0 to t2 (Figure 1). During this follow-up, four
individuals developed a moderate disease and four indivi-
duals got a severe form of the same disease. Therefore, the
true risk ratio between the risk of severe disease and that of
moderate disease is 1. However, people with severe disease
have a higher risk to die, and before the time ‘t1’, two
individuals died. If at time ‘t1’ we perform a cross-sectional
analysis (survey), we get a prevalence ratio of severe versus
moderate disease of 0.5 (in fact at time ‘t1’ we have only one
case with severe disease and two cases with moderate
disease), a figure that does not reflect the true risk ratio that
is 1. Therefore, whenever possible we should estimate the
occurrence of a disease in terms of incidence, that is by
counting all cases that occur in a sample in a given time
interval rather than in a given time point.
As further example of incidence-prevalence bias, we can
consider the following one.
Example 2: In a case–control study, Ibanez et al.3 assessed
the association between chronic use of Aspirin and
occurrence of end-stage renal disease (ESRD).
An OR of 1.74 means that the odds of exposure to Aspirin
were 74% higher in individuals with ESRD than in those
without this complication. In this study, the selection process
of cases and controls as well as the assessment of exposure
status were performed in an appropriate manner, thus we can
assume that this OR reflects the situation in the reference
population, that is we can look at this OR as the ‘true’ OR.
We now consider a hypothetical situation where the selection
of cases from the target population, but not that of controls,
is biased because it is affected by previous knowledge by the
investigator of the exposure status. In other words, the
investigator, influenced by his knowledge of the exposure
status, tends to gather cases mainly among individuals known
to be Aspirin users.
Bias in the selection of cases produces a considerable
alteration in the estimate of the OR (3.15 versus 1.74). To
avoid this problem, the selection process of cases and controls
from the target population should be rigorously the same and
should be independent from the exposure status (i.e. the
investigator should be blinded to the exposure status). This
type of bias, which we herein describe in relationship with
case–control studies, can occur with any type of study design.
Loss-to-follow-up bias
This bias occurs in prospective cohort studies when
individuals lost to follow-up do not have the same
probability of having the clinical outcome of interest in
comparison with individuals who remain under observation.
We consider a hypothetical prospective study aimed at
determining the incidence rate of renal insufficiency in
hypertensive and normotensive individuals. It is well known
that in this type of study the follow-up duration must be
extended to several years. As a consequence, normotensives
who did not develop any disease after several years of
observation may be less stimulated to continue the study
while hypertensives, who most likely develop comorbid
conditions, can be more motivated to continue the study
participation. Thus, loss-to-follow-up bias may distort the
true risk of renal insufficiency in hypertensive versus
normotensive individuals. In the recent literature, a potential
source of loss-to-follow-up bias can be found in the CHOIR
study (a randomized clinical trial testing the effect of anemia
correction in patients with chronic kidney disease not
receiving dialysis).4 The CHOIR protocol terminated the
follow-up of all individuals who achieved ESRD, thus
Disease status
With ESRD
(cases)
Without ESRD
(controls)
Users of Aspirin 81 94
Nonusers of Aspirin 439 888
Total 520 982
In this study, the odds ratio (OR) of the use of Aspirin is: OR=(81/439)/(94/888)=1.74.
Disease status
With ESRD
(cases)
Without ESRD
(controls)
Users of Aspirin 130 94
Nonusers of Aspirin 390 888
Total 520 982
The OR in this situation is (130/390)/(94/888)=3.15.
Original sample
(n=20)
Survey
(cross-sectional analysis)
New case of moderate disease
New case of severe disease
Death
Time 0……………………………… t1…………………………t2
Figure 1 | A hypothetical example of incidence-prevalence bias.
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potentially generating a bias. In fact, although the relative
impact of the intervention was unaffected by this bias (the
proportion of excluded ESRD patients was similar between
the two CHOIR study arms: 18 versus 15%), this was not true
for the cumulative incidence of events in the two groups that
was influenced by censoring ESRD patients.
Publication bias
This bias is generally considered as a selection bias. Indeed,
the acceptance of the validity of published findings as applied
to a given reference population is conditional not only on the
fact that each published study is unbiased but also that
published studies constitute an unbiased sample of all studies
performed. When these assumptions are not met, a literature
review based on either meta-analytic or conventional
narrative approaches will give a distorted view of the
exposure-outcome association of interest.
Publication bias is generated in the selection process of the
information that is eventually published. Several factors
influence publication, the most important being study size
and design, quality, funding, and prestige.5
Example 3: Kasiske et al.6 collated 13 studies on lipid
lowering and renal outcomes in patients with chronic kidney
disease. In this systematic review, only 2 studies out of 11 (i.e.
18%) reported a negative effect of treatment on albuminuria
or proteinuria. A possible explanation for this phenomenon
is that journal editors might have been biased in accepting
studies reporting a negative effect of treatment or, alterna-
tively, that authors of negative studies might have not
submitted them because of the low probability for these
studies to be accepted.
The simplest and most commonly used method to detect
publication bias is the funnel plot.7,8 A funnel plot is a graph
where the effect of a given treatment of each trial is plotted
against some measure of its size, such as the precision, the
standard error, or the overall sample size. These plots are
referred to as funnel plots because they should be shaped like
a funnel if no publication bias is present. This shape is
expected because the estimate of the effect of a treatment has
a larger variability in smaller studies. Since smaller and
negative studies are less likely to be published, trials in the
bottom left-hand corner of the graph are often omitted,
creating a degree of asymmetry in the funnel. In Figure 2 we
report a hypothetical example of publication bias. In the left-
hand side of Figure 2, the shape of the plot suggests that
smaller studies indicating a worse outcome with the
treatment being tested might not have been reported (just
one study where treatment produced worse outcome). In the
right-hand side of Figure 2, there are smaller studies showing
either beneficial or no beneficial effects of the treatment. In
this case the plot is appropriately funnel-shaped, making
publication bias less likely.
INFORMATION BIAS
Information bias occurs during data collection. There are two
(main) types of information bias: misclassification bias and
lead-time bias.
Misclassification
Misclassification bias originates when the process to detect
the exposure status (exposure identification bias) and/or the
outcome (outcome identification bias) is imperfect, that is,
exposed/diseased individuals are classified as nonexposed/
nondiseased and vice versa. A potential source of misclassi-
fication can be the use of an inaccurate instrumentation, such
as using only one size BP cuff to take measurements on both
lean and obese adults. As an effect of the inappropriate size of
cuff we can classify a normotensive individual as hypertensive
and vice versa. Misclassification can be nondifferential or
differential. In the example below we refer to misclassifica-
tion of exposure.
Nondifferential misclassification. Nondifferential misclassi-
fication occurs when the misclassification of exposure is
independent of disease status, that is, it is the same in
diseased individuals (cases) and nondiseased individuals
(controls).
Example 4: Consider a hypothetical case–control study
investigating the association between hypertension and renal
dysfunction.
The OR indicates that the odds of exposure to hyperten-
sion are 5.00 times higher in cases than in controls and, in the
absence of misclassification, we consider this OR as the true
OR. Now, we can hypothesize a situation in which the
misclassification of the exposure is equally frequent in cases
Measure of effect
Better
Sample size
(log scale)
Publication bias
Worse
0 50 100 1000
Measure of effect
Better
Sample size
(log scale)
No publication bias
Worse
0 100 100050
Figure 2 | A hypothetical example of funnel plot. Left panel: the
shape of the plot suggests that smaller studies indicating a worse
outcome with the treatment being tested, might not have been
reported (just one study where treatment produced worse outcome)
(publication bias); right panel: there are smaller studies showing
either beneficial or no beneficial effects of the treatment (no
publication bias).
With renal dysfunction
(cases)
With normal renal function
(controls)
Hypertensives 40 10
Normotensives 40 50
OR=(40/40)/(10/50)=5.00.
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and controls, that is, in 30% of hypertensives with renal
dysfunction (n¼ 12) and in 30% of hypertensives with
normal renal function (n¼ 3). Since the misclassification of
the exposure is identical in cases and controls it is said to be
‘nondifferential’. This new situation is illustrated below:
This OR is lower than the ‘true’ OR (4.10 instead of 5.00).
In fact, nondifferential misclassification of exposure always
leads to an underestimation of the strength of the association
between the exposure and the disease, that is, the RR and the
OR tend toward 1.
Differential misclassification. Differential misclassification
occurs when the misclassification of exposure differs between
cases and controls.
For example, we consider that there is a 30% exposure
misclassification only in controls.
Here, differential misclassification leads to an overestima-
tion of the strength of the association between exposure and
disease. By contrast, if misclassification occurs in cases but
not in controls, the resulting OR leads to an underestimation
of the strength of the same association. In summary,
differential misclassification may either increase or decrease
the strength of reported associations depending on the
direction of the misclassification. Differential misclassifica-
tion can also occur in cohort studies if exposed and
unexposed individuals are misclassified.
The most common biases producing misclassification are
the following:
Recall bias: Recall bias results from imprecise memory of
past exposure and is of particular concern in case–control
studies. For example, a patient with glomerulonephritis may
have gone through all his exposures in his head once the
diagnosis was made to try to understand ‘Why me?’ An
individual without illness might not have that memory due
to limited reason to stretch to recall exposures. Methods used
to prevent recall bias include (a) verification of responses
from study individuals by using hospital records or other
reliable sources of clinical information; (b) use of diseased
controls. Patients (cases) are much more prone to remember
relevant exposures than healthy controls. Therefore, a control
group composed of individuals affected by a disease different
from that of cases can be used to introduce a similar bias, also
in the odds of exposure of controls; and (c) use of objective
markers of exposure. For example, in a hypothetical case–-
control study, investigating the association between exposure
to hydrocarbons and the risk of glomerulonephritis we can
estimate exposure to hydrocarbon by measuring metabolites
of this compound in biological samples.
Interviewer bias: This is the tendency of the interviewer to
obtain answers that support preconceived notions. Inter-
viewer bias may happen as a consequence of trying to ‘clarify’
questions when such clarifications are not part of the study
protocol, or when certain words are more emphasized during
the interview of cases but not of controls (or vice versa). For
example an interviewer testing the hypothesis that hydro-
carbon exposure may cause glomerulonephritis may adopt a
more inquisitive attitude in cases than in controls, thus
making the ascertainment of exposure more likely in diseased
than in nondiseased individuals. To avoid interviewer bias,
we should carefully standardize the interview and use an
identical approach in cases and controls. Furthermore, the
interviewer should be blinded to the case–control status.
Observer bias: Knowledge of exposure status by the
outcome assessor may influence the assessment process and
therefore produce biased results. An obvious example is the
assignment of a kidney biopsy specimen to a diagnosis of
hypertensive nephropathy where the pathologist knows that
the patient has a long history of hypertension. Possible
remedies to observer bias are the following: (1) blinding the
outcome assessor to exposure status; (2) when applicable,
labeling the outcome as ‘possible’, ‘probable’, and ‘definite’.
Observer bias should be suspected if results emerge in the
‘possible’ category only; and (3) involving multiple outcome
assessors.
Regression dilution bias: It is well known that a variable
that shows an extreme value on its first measurement will
tend to be less extreme on subsequent assessments (‘regres-
sion to the mean’ phenomenon). The regression dilution bias
is related to regression to the mean and originates in
longitudinal studies investigating the association between
baseline measurements of a continuous variable and the risk
of a given outcome. A classical example of this bias is the
association between systolic pressure and the risk of
myocardial infarction. During the baseline assessment of
systolic pressure we have two sources of variations: variations
in the measurement of arterial pressure among individuals
and deviations between the baseline and the usual arterial
pressure level within each individual. Regression to the mean
refers to the noise introduced by within individual variation.
It is the tendency for high values of continuous variables (like
BP) measured at a given time point to decrease and for low
values to increase, when repeated measurements are per-
formed. As a consequence of the ‘regression to the mean’,
With renal dysfunction
(cases)
With normal renal function
(controls)
Hypertensives 4012=28 103=7
Normotensives 40+12=52 50+3=53
OR=(28/52)/(7/53)=4.10.
With renal dysfunction
(cases)
With normal renal function
(controls)
Hypertensives 40 103=7
Normotensives 40 50+3=53
OR=(40/40)/(7/53)=7.58.
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individuals in the top category of BP level frequently show
higher systolic pressure at the first visit than at the second,
while individuals in the bottom category have a systolic
pressure at the first visit, which is somewhat lower than that
at the second visit: in other words many values converge
(regress) toward the mean (Figure 3). Thus, if patients were
classified as hypertensive and normotensive on the basis of
BP measurement at the first visit, we would have mis-
classification of exposure (normotensives erroneously classi-
fied as hypertensives and vice versa). As further example, we
can consider a sample of individuals in which everyone
usually has a creatinine of 0.9 mg dl1. However, at this
particular moment of blood sampling some values were
higher due to a steak from last night’s dinner or volume
depletion, whereas others were lower due to pregnancy or
steroid use for muscle building. If we were to take only those
individuals with creatinine X1 mg dl1 and follow them,
they will all fall back to their true baseline values of
0.9 mg dl1 eventually and we would erroneously claim that
their kidney function improved. The regression dilution bias
always produces an underestimation of the true effect. To
avoid the regression dilution bias, the classification of
patients should be based on more than one BP measurement.
Lead-time bias
Another important information bias, which may occur in
prospective studies aimed at evaluating the efficacy of
screening, is the lead-time bias. This is the added time of
illness attributable to the fact that we apply to selected
patients different criteria for the diagnosis of the disease (i.e.
diagnosis made in the latency period or in the early phase
versus diagnosis made at an advanced stage).
Example 5: A subject gets diseased after a given time and
the disease is diagnosed because of symptoms (Figure 4). The
disease is a serious one and the patient dies quite soon after
diagnosis. The dead person was young and this causes sorrow
and concern in the community where he/she lived.
Experience with this first case prompts a screening program
to detect the disease at an early, pre-clinical stage. In the
second subject, disease is diagnosed during the screening
program at an asymptomatic stage.
The second patient receives some form of treatment but
the disease progresses until death. The survival from
diagnosis in this case is much longer than in the first case,
and we may be tempted to conclude that early diagnosis
was useful. In fact this is so because we applied different
criteria for the detection of the disease, that is, we diagnosed
it at a symptomatic phase in the first patient and at a pre-
clinical, asymptomatic phase in the second patient. It is
therefore possible that had we diagnosed the disease at a pre-
clinical stage in both patients, the survival might have been
identical. Thus, if we are going to assess the usefulness of a
screening program we should take into proper account the
‘lead time’. Lead-time bias may be a problem in studies
examining the effect of early referral on the outcome of
chronic kidney disease.9 If we do not appropriately account
for the phase of disease when chronic kidney disease is
diagnosed, we may overestimate the beneficial effect of early
referral.
To avoid the lead-time bias we can calculate the risk (or
rate) of mortality in all screened and control individuals
rather than the cumulative probability of survival from
diagnosis in cases.
SUMMARY
Bias appears a pervasive problem in clinical research. Bias can
be prevented at two levels: (1) by choosing the appropriate
study design for addressing the study hypothesis and (2) by
carefully establishing the procedures of data handling and the
definitions of exposures and outcomes.
Suspecting bias is an important aspect of critical appraisal
and this attitude is precious to properly evaluate clinical and
epidemiological studies.
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